Washington University School of Medicine

Digital Commons@Becker
2020-Current year OA Pubs

Open Access Publications

7-1-2022

Mitochondrial RNA modifications shape metabolic plasticity in
metastasis
Sylvain Delaunay
Deutsches Krebsforschungszentrum

Gloria Pascual
The Barcelona Institute of Science and Technology

Bohai Feng
Zhejiang University

Kevin Klann
Goethe University Frankfurt

Mikaela Behm
Deutsches Krebsforschungszentrum

See next page for additional authors
Follow this and additional works at: https://digitalcommons.wustl.edu/oa_4
Part of the Medicine and Health Sciences Commons

Recommended Citation
Delaunay, Sylvain; Pascual, Gloria; Feng, Bohai; Klann, Kevin; Behm, Mikaela; Hotz-Wagenblatt, Agnes;
Richter, Karsten; Zaoui, Karim; Herpel, Esther; Münch, Christian; Dietmann, Sabine; Hess, Jochen; Benitah,
Salvador Aznar; and Frye, Michaela, "Mitochondrial RNA modifications shape metabolic plasticity in
metastasis." Nature. 607, 7919. 593 - 603. (2022).
https://digitalcommons.wustl.edu/oa_4/50

This Open Access Publication is brought to you for free and open access by the Open Access Publications at
Digital Commons@Becker. It has been accepted for inclusion in 2020-Current year OA Pubs by an authorized
administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.

Authors
Sylvain Delaunay, Gloria Pascual, Bohai Feng, Kevin Klann, Mikaela Behm, Agnes Hotz-Wagenblatt,
Karsten Richter, Karim Zaoui, Esther Herpel, Christian Münch, Sabine Dietmann, Jochen Hess, Salvador
Aznar Benitah, and Michaela Frye

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/oa_4/50

Article

Mitochondrial RNA modifications shape
metabolic plasticity in metastasis


https://doi.org/10.1038/s41586-022-04898-5
Received: 27 October 2020
Accepted: 24 May 2022

Published online: 29 June 2022
Open access
Check for updates
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Agnes Hotz-Wagenblatt1, Karsten Richter1, Karim Zaoui3, Esther Herpel6,7, Christian Münch5,
Sabine Dietmann8, Jochen Hess1,3, Salvador Aznar Benitah2,9 & Michaela Frye1 ✉

Aggressive and metastatic cancers show enhanced metabolic plasticity1, but the
precise underlying mechanisms of this remain unclear. Here we show how two
NOP2/Sun RNA methyltransferase 3 (NSUN3)-dependent RNA modifications—
5-methylcytosine (m5C) and its derivative 5-formylcytosine (f5C) (refs.2–4)—drive the
translation of mitochondrial mRNA to power metastasis. Translation of
mitochondrially encoded subunits of the oxidative phosphorylation complex
depends on the formation of m5C at position 34 in mitochondrial tRNAMet.
m5C-deficient human oral cancer cells exhibit increased levels of glycolysis and
changes in their mitochondrial function that do not affect cell viability or primary
tumour growth in vivo; however, metabolic plasticity is severely impaired as
mitochondrial m5C-deficient tumours do not metastasize efficiently. We discovered
that CD36-dependent non-dividing, metastasis-initiating tumour cells require
mitochondrial m5C to activate invasion and dissemination. Moreover, a
mitochondria-driven gene signature in patients with head and neck cancer is
predictive for metastasis and disease progression. Finally, we confirm that this
metabolic switch that allows the metastasis of tumour cells can be pharmacologically
targeted through the inhibition of mitochondrial mRNA translation in vivo. Together,
our results reveal that site-specific mitochondrial RNA modifications could be
therapeutic targets to combat metastasis.

Metastasis is the main cause of cancer-related deaths5. As a multistep
process, metastasis begins with the invasion of tumour cells through
the basement membrane and intravasation into the surrounding
vasculature or lymphatic system, and ends with colonization at secondary
tumour sites5. To successfully metastasize, tumour cells must dynamically adapt to the constantly changing microenvironment1. Metabolic
plasticity allows tumour cells to survive in adverse conditions, including
hypoxia and starvation, in particular during proliferation-independent
processes such as dissemination from the primary tumour1,6.
Mitochondria are bioenergetic, biosynthetic and signalling organelles that are integral to stress sensing. Because mitochondria allow
fast cellular adaptations to environmental cues, they are important
mediators of most aspects of tumorigenesis7. For example, mitochondrial translation efficiency is vital for controlling cytosolic protein
homeostasis and nuclear stress signalling, and thereby directly determines cellular lifespan8. However, the precise molecular mechanisms
that underlie how human tumour cells rapidly adjust the balance
between mitochondrial and glycolytic energy production remain
largely unclear.
The mitochondrial metabolic pathway of oxidative phosphorylation (OXPHOS) contains over 100 proteins. The mitochondrion itself

translates 13 OXPHOS subunits. To translate these essential subunits
of the respiratory chain complex, the mitochondrial genome contains
22 tRNAs that get modified at 137 positions by 18 types of RNA modifications9. The function of these RNA modifications is to determine the
accuracy and optimal rate of translation10. The mitochondrial protein synthesis machinery differs in many ways from translation in the
cytoplasm. For instance, human mitochondria only use one tRNA
(tRNAMetCAU) to read AUG and AUA codons as methionine11. To decipher
AUA as methionine, mitochondrial tRNAMet contains the RNA modification f5C at the wobble position of the anticodon (position 34). As f5C34
enables tRNAMet to recognize AUA as well as AUG codons, the modification regulates both translation initiation and elongation efficiency2,12.
The biogenesis of f5C34 is initiated through the formation of m5C by
NSUN3, and is completed by ALKBH1 (refs. 2–4,13). Loss-of-function
mutations in the human NSUN3 gene are linked to deficiencies in the
mitochondrial respiratory chain complex, which are caused by severe
defects in mitochondrial translation4. The functions of mitochondrial
tRNA modifications in cancer are at present largely unknown.
Here we show that mitochondrial cytosine-5 RNA methylation is
essential for the dynamic regulation of mitochondrial translation rates,
and thereby shapes metabolic reprogramming during metastasis. We
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reveal that tumour cells with low mitochondrial levels of m5C reduce
OXPHOS and rely on glycolysis for energy production instead. However,
the reverse metabolic switch from glycolysis to OXPHOS promotes
tumour cell invasion and metastasis. Only cancer cells that have high
levels of m5C and f5C, to enhance mitochondrial translation rates and
fuel OXPHOS, invade the extracellular matrix and disseminate from
primary tumours. Preventing the formation of m5C and pharmacological inhibition of mitochondrial translation both inhibit metastasis
in vivo. Together, our study shows that mitochondrial RNA modifications regulate the metabolic reprogramming that is required for the
invasion and dissemination of tumour cells from primary tumours.

Results

We confirmed that there was a significant decrease of nascent protein
synthesis in NSUN3-depleted mitochondria by quantifying the incorporation of O-propargyl-puromycin (OP-puro) into nascent peptide
chains (Fig. 2a,b and Extended Data Fig. 2a,b). Thus, hypomethylation
of mt-tRNAMet downregulates the protein levels of mitochondrially
encoded genes2–4.
To test how the mitochondrial metabolism adapted to the downregulation of protein synthesis, we quantified metabolites of the tricarboxylic acid (TCA) cycle using mass spectrometry (Extended Data Fig. 2c).
We measured a slight reduction in most TCA metabolites when the
expression of NSUN3 was reduced (Fig. 2c). To confirm that m5C directly
regulated mitochondrial activity, we overexpressed a wild-type (WT) or
an enzymatic dead (MUT) version of the NSUN3 protein4 (Extended Data
Fig. 2d–f). Similar to NSUN3 depletion, TCA metabolite levels were also
lower in methylation-deficient cells (Fig. 2c). Consequently, maximal
cellular respiration was reduced when mt-tRNAMet was hypomodified
(Fig. 2d,e and Extended Data Fig. 2j,k), and the basal extracellular
acidification rate (ECAR) was higher overall in NSUN3-deficient cancer cells (Fig. 2f and Extended Data Fig. 2g–i,l–o). The differences in
mitochondrial metabolism were not driven by increased cell death,
altered mitochondrial DNA copy number or enhanced production of
reactive oxygen species (ROS) (Extended Data Fig. 3a–c). Instead, the
cancer cells directly rebalanced their overall ATP production towards
glycolysis (Fig. 2g).
Mitochondria adapt their shape and structure to sustain their cellular
functions17. Accordingly, we measured a significant reduction in mitochondria length in cells that overexpressed methylation-deficient
NSUN3 (Extended Data Fig. 3d,e). Similarly, the morphology of mitochondria in NSUN3-deficient cells appeared more circular and the
number of cristae per mitochondrion was decreased (Fig. 2h–k and
Extended Data Fig. 3f–k). We conclude that the RNA modifications m5C
and f5C in mt-tRNAMet act as a sensor of cellular energy requirements
and adapt mitochondrial functions accordingly (Fig. 1l).

Cytosine modifications in mitochondrial tRNAMet
f5C is a unique tRNA modification in mammalian mitochondria
that derives directly from m5C (ref.9). To simultaneously detect
f5C and m5C at single-nucleotide resolution, we performed chemically assisted bisulfite sequencing (fCAB-seq), a method that uses
O-ethylhydroxylamine to protect f5C sites in bisulfite conversion
protocols14 (Extended Data Fig. 1a). Out of all mitochondrial encoded
tRNAs, only two showed consistently high levels of modification
in normal and cancer cells (Fig. 1a and Extended Data Fig. 1b,c). As
expected, one site corresponded to cytosine 34 (C34) in the ‘wobble
position’ of mitochondrial (mt)-tRNAMet (Fig. 1a,b). The second site
corresponded to mt-tRNASer2, which does not carry f5C but contains
three NSUN2-mediated consecutive m5C sites in the variable loop15
(Extended Data Fig. 1d). Thus, our data confirm that tRNAMet is the only
mitochondrial tRNA that carries f5C.
To quantify f5C and m5C modifications individually, we next performed bisulfite RNA sequencing (RNA-seq) alongside fCAB-seq. The
levels of f5C are calculated by subtracting bisulfite-protected cytosines
from O-ethylhydroxylamine-protected sites (Fig. 1c–j). The most
prevalent modification in mitochondrial tRNAMet was m5C (more than
50%), followed by f5C (around 35%) and unmodified cytosines (less
than 10%) in all tested cell lines (Fig. 1c–j). To inhibit the formation of
both tRNAMet modifications, we depleted the methyltransferase NSUN3
in four oral squamous cell carcinoma (OSCC) cell lines using two different short hairpin RNAs (shRNAs) (Extended Data Fig. 1e). Parallel
bisulfite RNA-seq and fCAB-seq revealed an increase of around eightfold
in unmodified cytosines at position C34 when NSUN3 was depleted
(Fig. 1k–n and Extended Data Fig. 1e–h). Notably, the f5C modification
was virtually absent in mt-tRNAMet in NSUN3-depleted cells (Fig. 1k–n).
NSUN3 and ALKBH1 form an enzymatic cascade to synthesize f5C34
(refs. 2–4,13), but we did not detect equal stoichiometry of m5C and f5C
(Fig. 1c–j). To test whether the expression of ALKBH1 was compromised in cancer cells, we measured the RNA levels of NSUN3 and ALKBH1
(Extended Data Fig. 1i). Although the RNA levels of both enzymes
increased in cancer cells, the expression of NSUN3 was more variable
(Extended Data Fig. 1i). In addition, ALKBH1 expression was largely unaffected when NSUN3 was depleted (Extended Data Fig. 1j). ALKBH1 and
NSUN3 protein levels correlated in cancer cell lines16 (Cancer Cell Line
Encyclopedia) (Extended Data Fig. 1k), and a significant correlation of
expression was also present in oesophageal carcinoma and head and
neck squamous cell carcinoma (HNSCC) datasets, as well as the corresponding normal tissues (Extended Data Fig. 1l,m). We conclude that
NSUN3 and ALKBH1 are co-expressed, but that their enzymatic activity
or import into mitochondria may be differently regulated.
Together, our data show that depletion of NSUN3 causes a robust
reduction of both m5C and f5C at C34 in mitochondrial tRNAMet.

Mitochondrial m5C regulates metastasis
Owing to their integral role in stress sensing, mitochondria have
been implicated in most aspects of tumorigenesis7. To investigate
which stages of tumorigenesis involved m5C, we performed orthotopic transplantation assays into host mice18. We transplanted three
NSUN3-deficient human metastatic OSCC lines: SCC25 and the
patient-derived lines VDH01 and VDH15 (ref. 18; Fig. 3a and Extended
Data Fig. 4a). In addition, we overexpressed the wild-type (WT) or enzymatic dead (MUT) NSUN3 protein to identify methylation-dependent
cellular functions during tumorigenesis4 (Fig. 3a).
All human cancer lines formed tumours with 100% penetrance and
the vast majority (around 75%) formed metastases (Supplementary
Table 1). Metastases into both the lymph nodes and lungs were consistently decreased in tumours that lacked a functional NSUN3 protein
(Fig. 3a,b, Extended Data Fig. 4a,b and Supplementary Table 1). On
average, inhibition of mitochondrial m5C formation reduced the development of lymph node metastasis from 80% to 20% (Fig. 3b, Extended
Data Fig. 4b and Supplementary Table 1). However, primary tumour
growth was largely unaffected (Extended Data Fig. 4d–f). To fully
exclude the possibility that differences in metastases were driven by
primary tumour size, we normalized the dimension of the secondary
tumour to its matching primary tumour. This ratio was consistently
lower when NSUN3 was depleted or inhibited (Fig. 3c and Extended
Data Fig. 4c). We conclude that mitochondrial tRNAMet modifications
at C34 are required for efficient tumour metastasis, but not for primary
tumour development and growth.

m5C modulates mitochondrial function
As mt-tRNAMet is needed for both translation inititation and elongation
of mitochondrial mRNA, we asked whether loss of m5C, and consequently also f5C, affected global rates of mitochondrial translation.

m5C and f5C-deficient tumours are glycolytic
To understand how tumour formation was affected by reduced
levels of m5C in mitochondria, we histologically examined the primary tumours. Consistent with our observation that inhibition of
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Fig. 1 | Detection of m5C and f5C in mitochondrial tRNAs. a, Detection of m5C
and f5C sites in the mitochondrial tRNA transcriptome using fCAB-seq in cancer
cells (VDH01). Plotted are all cytosines with a coverage of more than 100 in both
independent replicates. The two peaks correspond to C34 of mt-tRNAMet
mediated by NSUN3 and C47, C48 and C49 in mt-tRNASer2 mediated by NSUN2,
respectively. b, Mitochondrial tRNAMet secondary structure with all known
modifications highlighted in red. c,d, Schematic overview of m5C (c) and f5C

(d) formation. SAM, S-adenosyl-l-methionine; SAH, S-adenosyl-l-homocysteine.
e–n, Heat maps (e,g,i,k,m) of mt-tRNAMet centred on position C34 and adjacent
cytosines showing modified (blue) and unmodified (grey) cytosines from
gene-specific parallel fCAB-seq and bisulfite sequencing (BS-seq) in the
indicated cell lines; and quantification (f,h,j,l,n) of cytosines that are
unmodified, m5C- or f5C-modified as shown in the heat maps (average of three
sequencing reactions per condition).

methylation enhanced glycolysis in vitro, NSUN3-depleted tumours
also exhibited an increase in glycolysis and upregulation of glucose
transporter 1 (GLUT1) in vivo (Fig. 3d,e and Extended Data Fig. 4g). As
cancer cells readily use glycolysis for energy production, even when
oxygen is available (the Warburg effect), it was unsurprising that
primary tumour growth was unaffected by the loss of NSUN3. Accordingly, NSUN3-depleted primary tumours were histologically highly
similar to controls (Extended Data Fig. 4h–t).
To identify mitochondria-driven gene expression signatures that
correlated with metastasis, we transcriptionally profiled the primary
tumours expressing or lacking NSUN3 (Extended Data Fig. 5a–f and
Supplementary Table 2). We identified a set of 1,708 transcripts that
were commonly deregulated in NSUN3-depleted tumours (Extended
Data Fig. 5g). As expected, the differentially expressed transcripts
were enriched for genes that encode regulators of mitochondrial
activity such as NADH dehydrogenase, oxidoreductase and electron
transfer (Extended Data Fig. 5h). The most significantly enriched
Gene Ontology (GO) category comprised genes that encode structural constituents of both mitochondrial and cytoplasmic ribosomes (GO:0003735; Extended Data Fig. 5h). Notably, all identified
ribosomal regulators were downregulated in the absence of NSUN3

(Extended Data Fig. 5i), confirming that global protein homeostasis
had adapted to low levels of protein synthesis in the mitochondria.
Principal component analyses using all transcribed mitochondrial
genes (n = 1158; MitoCarta2.0) clearly separated the tumours according to NSUN3 expression (Extended Data Fig. 5j), an effect that was
highly reproducible and independent of the shRNA (Extended Data
Fig. 5k).
We next assessed how the mitochondrion itself was affected by
NSUN3 depletion. RNAs that encode proteins of the OXPHOS pathway were the most repressed in the absence of NSUN3 (Fig. 3f,g). All
mitochondrially encoded proteins that form complex I, III, IV and V were
downregulated (Fig. 3g). The only exception was complex II, which does
not contain mitochondrially encoded subunits and was therefore not
directly affected by the depletion of NSUN3 (Fig. 3g). Gene set enrichment analysis (GSEA) further confirmed a decrease in the expression
of OXPHOS regulators, but also identified positive correlations with
regulators of hypoxia and inhibitors of metastasis (Fig. 3h).
Thus, our data show that the transcriptional profile of NSUN3depleted tumours is driven by mitochondrial activity, and that hypomodified mitochondrial tRNAMet metabolically reprograms primary
tumours.
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Mitochondrial m5C fuels invasion
To determine which tumour cell population relied most on high mitochondrial translation levels, we labelled primary tumour sections
for the mitochondrial markers MTCO1 and MTCO2. Both markers
co-localized with CD44 and were most highly expressed in the basal
layers of the tumours (Extended Data Fig. 6a–d). The basal layer contains undifferentiated, proliferating cells but also initiates invasion
during metastasis. To study whether cell proliferation or invasion was
affected by inhibition of mitochondrial m5C formation, we subjected
the OSCC cells to three-dimensional (3D) culture systems (Fig. 4a).
All spheres (tumoroids) were comparable in size, even when NSUN3
was depleted or m5C formation inhibited, which confirms that cell
proliferation was largely unaffected (Extended Data Fig. 6e–l). Similar
to our findings in 2D-cultured cells and tumours formed in vivo, the
spheres also switched to glycolysis in the absence of NSUN3, as shown

by enhanced uptake of glucose (Extended Data Fig. 6m–p). To visualize
mitochondrial activity in the tumoroids, we measured the mitochondrial membrane potential (MMP) through incorporation of the dye
MitoTracker CMXROS. The MMP was highest in a small number of cells
at the surface of the tumoroids (Fig. 4b and Extended Data Fig. 7a–k),
and those cells disappeared in the absence of NSUN3 (Fig. 4c,d).
Mitochondria are involved in both the migration and the invasion of
tumour cells19. Therefore, we tested the capacity of the tumoroids to
disseminate cells for invasion by embedding them into a 3D collagen I
matrix20 (Fig. 4e,f). Invading leader cells showed an upregulation of the
MMP and increased mitochondrial lengths (Fig. 4f–i). Both depletion
and inhibition of NSUN3 significantly reduced the number of leader
cells per tumoroid (Fig. 4j–l and Extended Data Fig. 7l–n). Thus, high
levels of mitochondrial tRNAMet modifications promoted tumour cell
invasion.
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or tumours; sh#1: n = 3 mice or tumours). Scale bars, 50 μm. f, Illustration of
mitochondrial compartments (top) and GSEA showing the normalized average
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Exact P values are indicated.

m5C regulates CD36-driven metastasis
A subpopulation of non-dividing tumour cells co-expressing
the cell-surface markers CD44 and CD36 has been identified as
metastasis-initiating cells in human oral carcinoma18. As CD36 is
located on the outer mitochondrial membrane21, we next tested
whether the CD44- and CD36-expressing population correlated with
mitochondrial functions. To measure the mitochondrial activity in
CD44+CD36+ tumour cells, we first sorted cancer cells for high (H)

or low (L) expression of CD44 and CD36 (Fig. 5a,b), and then quantified the MMP in the different subpopulations. CD44HCD36H cells
were consistently the population with the highest MMP (Fig. 5b,c and
Extended Data Fig. 8a–c). Accordingly, expression of NSUN3 and the
mitochondrial regulators MT-CO1 and TFAM were also upregulated
in the CD44HCD36H population (Fig. 5d and Extended Data Fig. 8d,e).
Other highly expressed markers included the cell adhesion protein
integrin-α6 (ITGA6) and the regulator of epithelial-to-mesenchymal
transition SLUG (Extended Data Fig. 8e).
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Next, we asked whether mitochondrial m5C and f5C levels maintained
the metastasis-initiating CD44HCD36H cell population. Knockdown
of NSUN3 was sufficient to downregulate the mRNA levels of both
CD44 and CD36 (Extended Data Fig. 8f,g). The number of CD44HCD36H cells was about threefold lower in the absence of NSUN3
(Fig. 5e and Extended Data Fig. 8h–j). Similarly, overexpression of the
methylation-deficient but not the wild-type NSUN3 protein reduced
the number of CD44HCD36H cells by more than fourfold (Extended
Data Fig. 8k–m). Finally, we also analysed orthotopically transplanted
tumours and their matching lymph node metastases for CD44HCD36H
cells (Fig. 5f). Both depletion and inhibition of NSUN3 reduced the
number of CD44HCD36H cells by threefold (Fig. 5g). Notably, the lymph
node metastases and their matching primary tumours contained a
comparable number of CD44HCD36H cells, indicating that the formation of the double-positive metastasis-initiating cell population was
reversible (Fig. 5h). Together, our data show that depletion of the mitochondrial RNA modifications m5C and f5C is sufficient to diminish the
metastasis-initiating cell population.

in all three subpopulations (CD44HCD36H, CD44HCD36L and CD44LCD36L) in tumoroids using a comparative quantitative proteomics
approach23 (Fig. 5i and Supplementary Table 3). Hierarchical clustering
of the subpopulation’s proteome segregated newly translated mRNAs
into seven different clusters (Fig. 5j and Supplementary Table 4). Only
cluster 3 contained mRNAs for which the translation rates progressively
increased, with the rate being highest in CD44HCD36H cells (Fig. 5j).
Proteins involved in regulating mitochondrial activity were significantly
enriched in cluster 3 (Fig. 5k and Extended Data Fig. 9a–e). Cluster
analyses using all translated mitochondrial genes (MitoCarta2.0) present in all replicates and conditions (n = 656) confirmed a consecutive
translational upregulation of mitochondria-related proteins, with
metastasis-initiating cells (CD44HCD36H) having the highest translation
rates (Fig. 5l). Thus, CD36-driven metastasis-initiating cells are defined
by a metabolic translatome that promotes mitochondrial respiration.
Our data so far have linked mitochondrial activity to the CD44HCD36H
metastasis-initiating tumour cells, but it is unclear whether the
downregulation of CD36 is a cause or a consequence of m5C- and
f5C-dependent mitochondrial metabolic reprogramming. To directly
test whether the reduction of the NSUN3-deficient metastasis-initiating
population was due to the downregulation of CD36 rather than the
loss of the mitochondrial RNA modifications, we stably overexpressed
CD36 in NSUN3-depleted cancer cells (Extended Data Fig. 9f–j). Overexpression of CD36 was not sufficient to rescue oxygen consumption
rates in NSUN3-depleted cells or alter tumoroid growth (Extended

Proteome of metastasis-initiating cells
The mitochondrial translation rate is intricately linked to nuclear
gene expression and cytosolic mRNA translation, and this cross-talk
is required to integrate mitochondrial activity into the cellular context22. To study how mRNA translation was altered in CD36-dependent
metastasis-initiating cells, we quantified nascent protein synthesis
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e,f, Frequency of the indicated pathological stages (e) and lymph node
metastases (LN-Met) (f) in clusters identified in d. g,h, Immunohistochemistry
for NSUN3 in primary HNSCC with metastases. Arrowheads, cells at the
tumour–stroma border. Black square, higher magnification shown in h. Dotted
line with arrow, tumour–stroma border. i, Strategy to quantify the Euclidian
distance of NSUN3+ and NSUN3− cells from the tumour–stroma border.
j, Proportion of NSUN3+ and NSUN3− cells at the indicated distance to the
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indicated.

Data Fig. 9k–m). Thus, CD36 signalling required NSUN3-dependent
mitochondrial changes.
As expected, overexpression of CD36 significantly induced the
formation of leader cells in invading tumoroids when the cells were
pre-treated with palmitate to activate CD36 signalling (Padj = 3.7 ×10−5)
(Fig. 5m,o and Extended Data Fig. 9n). However, CD36-driven activation
of invasion depended on the presence of NSUN3 (Fig. 5n,o). In conclusion,
upregulation of CD36 signalling was not sufficient to rescue the
invasion processes in NSUN3-depleted cells.
In summary, CD36 signalling requires the mitochondrial RNA
modifications m5C and f5C for palmitate-induced invasion of tumour
cells. Moreover, reducing mitochondrial RNA modification levels is
sufficient to diminish the metastasis-inducing tumour cell population.

of NSUN3 in a time-course experiment (Fig. 5p–r and Extended Data
Fig. 9o). We measured a significant decrease in CD44HCD36H cells six
days after NSUN3 depletion (Fig. 5q), but the number of viable cells
in the CD44HCD36H population remained unchanged (Fig. 5r). Thus,
the lack of metabolic plasticity in NSUN3-deficient cells inhibited
CD36-dependent invasion but it did not cause cell death.
We conclude that the metastasis-initiating CD44HCD36H population is dynamically formed within the primary tumour as a result of
metabolic events that require high levels of tRNAMet RNA modifications.

Metabolic reprogramming is dynamic
Our data have shown that low levels of m5C and f5C repress mitochondrial translation and thereby force tumour cells to use glycolysis as energy source, and that this metabolic pathway allows cell
growth, but prohibits cell invasion and metastasis. However, the fate
of NSUN3-depleted cells during invasion is unclear. To test whether
CD36 signalling in the absence of NSUN3 simply causes cell death,
we quantified the number of viable CD44HCD36H cells after depletion
600 | Nature | Vol 607 | 21 July 2022

NSUN3-driven gene signature in cancer
To assess the predictive value of mitochondrial m5C levels for metastasis in patients with HNSCC, we stained 78 tumour samples for NSUN3
(ref. 24). Expression of NSUN3 protein was highest in primary tumours
from patients with regional lymph node metastases at the time of
diagnosis, and was associated with higher pathological staging of
the primary tumours (Fig. 6a–c, Extended Data Fig. 10a,b and Supplementary Table 5). The levels of NSUN3 protein expression were
comparable in primary tumours and lymph node metastases (Extended
Data Fig. 10c,d), which corroborates our finding that orthotopically
transplanted tumours and their matching lymph node metastasis also
had similar proportions of CD36HCD44H cells (Fig. 5h).
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To define the clinical features of mitochondrial-driven transcriptional profiles, we identified all differentially expressed genes that
correlated with the levels of NSUN3 in patients with HNSCC (The Cancer Genome Atlas (TCGA); n = 500) (Extended Data Fig. 10e and Supplementary Table 6). As expected, the NSUN3-driven signature was
enriched for genes that encode regulators of metastasis and hypoxia
(Extended Data Fig. 10f and Supplementary Table 7). Unsupervised
clustering grouped the patients into four clusters according to the
NSUN3-driven gene signature (Fig. 6d and Extended Data Fig. 10g).
Both the pathological stage of these cancers and the presence of lymph
node metastasis at the time of diagnosis progressively increased with
NSUN3 levels (Fig. 6e,f).
To confirm our observation in tumoroids that metastasis-initiating
cells needed high mitochondrial activity for invasion (Fig. 3), we labelled
primary tumour sections from patients with lymph node metastasis
for NSUN3. NSUN3 protein levels were highest at the invasive front of
the tumours (Fig. 6g,h). When we measured the Euclidian distance
of NSUN3high and NSUN3low cells from the tumour–stroma border, we
found that the number of NSUN3high cells sharply increased at around
a 30-µm distance to the border (Fig. 6h–j). Together, our data indicate
that the activity of NSUN3 is higher close to the tumour–stroma border,
where the activation of invasion occurs.
In summary, the NSUN3-driven gene signature is prognostic for
lymph node metastasis and for higher pathological stage in patients
with HNSCC. Thus, we have identified a mitochondria-driven gene
signature that predicts lymph node colonization and progression-free
survival in head and neck cancer.

Mitochondria regulate metastasis
Small-molecule inhibitors of mitochondrial transcription reduce
tumour growth in xenografts of human cancer cells25, and mitochondrial protein synthesis has central roles in cancer development and
progression26. In stark contrast to these wide-ranging mitochondrial
functions in cancer, inhibiting mitochondrial mRNA translation by
targeting m5C and f5C in tRNAMet exclusively reduced tumour metastasis without affecting cell viability or primary tumour initiation and
growth. Therefore, we sought to exclude that other unknown functions
of NSUN3 contributed to tumour cell invasion and metastasis.
If regulating mitochondrial translation by modifying mt-tRNAMet is
the only function of NSUN3, then we should be able to recapitulate all
observed NSUN3-dependent cellular functions by specifically inhibiting
mitochondrial translation without affecting cytoplasmic protein
synthesis. Because mitochondrial and prokaryotic protein synthesis
machineries are highly similar, several classes of antibiotics such as
glycylcyclines, oxazolidinones and amphenicols also target mitochondrial ribosomes27,28 (Extended Data Fig. 11a). Indeed, only treatment of
cancer cells with linezolid (LIN), chloramphenicol (CAP), tigecycline
(TIG) or doxycycline (DOX) repressed mitochondrial protein synthesis,
reduced the oxidative phosphorylation capacity and increased the
extracellular acidification rate (Fig. 7a and Extended Data Fig. 11b–d).
Ampicillin (AMP) and amoxicillin (AMOX) both target the bacterial cell
wall, and mitochondrial translation and functions were unaffected by
those antibiotics (Fig. 7a and Extended Data Fig. 11d).
To study whether repression of mitochondrial translation affected
tumour cell invasion similarly to depletion or inhibition of NSUN3, we
Nature | Vol 607 | 21 July 2022 | 601

Article
exposed OSCC tumoroids to the antibiotics and measured their invasive
capacity. Only treatment with CAP, LIN, TIG and DOX reduced the number of invading leader cells in tumoroids and reduced glucose uptake
(Fig. 7b,c and Extended Data Fig. 11e–h). Moreover, the expression of
CD36 protein and the number of CD36-dependent metastasis-initiating
tumour cells (CD44HCD36H) were reduced about twofold when the cells
were exposed to CAP, DOX, LIN and TIG (Extended Data Fig. 11i–m). As
described for the depletion of NSUN3, cell viability was unaffected by
exposure to the antibiotics (Extended Data Fig. 12a,b).
Finally, we confirmed that treatment with the selected antibiotics
also reduced metastases in vivo. We injected two OSCC lines into
the tongues of host mice, waited seven days for establishment of
primary tumours and then treated the mice daily with TIG, DOX or
AMOX. Only treatment with TIG and DOX decreased the number of
lymph node metastases from 80% to 20%, whereas AMOX-treated and
vehicle-treated tumours showed similar metastasis capacities (Fig. 7d,e
and Supplementary Table 1). As described for the inhibition of m5C
formation, the reduction of lymph node metastases was not driven
by primary tumour size when mitochondrial translation was inhibited
(Fig. 7f and Extended Data Fig. 12c). In conclusion, inhibition of
mitochondrial translation fully recapitulated the loss of a functional
NSUN3 protein by preventing cell invasion and reducing the number of
CD36-dependent metastasis-initiating tumour cells in vitro and in vivo.
In summary, our data reveal that mitochondrial tRNA modifications
regulate mitochondrial translation rates and thereby drive the metabolic reprogramming that is required for metastasis. Moreover, we
identify the inhibition of m5C formation in mitochondria as a therapeutic opportunity to prevent the dissemination of tumour cells from
primary tumours.

Discussion
Here we show that the dynamic adjustment of mitochondrial RNA modification levels directly contributes to tumour malignancy by promoting
metastasis. In contrast to normal tissues, tumours rely to a large extent
on aerobic glycolysis to meet the energy demands required for cell
division and growth29. However, tumours also need a high degree of
metabolic plasticity when reacting to cues and stresses in their local
environment, which causes heterogeneity in the metabolic status
of tumour cells1. Although the oxidative phosphorylation pathway
strictly depends on both cytosolic and mitochondrial protein synthesis
machineries30, we reveal that reducing the levels of m5C in mitochondrial RNA is sufficient to prohibit the metabolic switch from glycolysis to OXPHOS. The consequence of the loss of metabolic plasticity
in tumour cells is a low metastatic capacity. We further reveal that
CD36-dependent metastasis-initiating cells require mitochondrial
m5C to activate invasion and dissemination from the primary tumour.
Upregulation of CD36 enhances the uptake of fatty acids for lipid
homeostasis but can also fuel mitochondrial respiration under stress
conditions31. CD36 expression correlates with poor patient survival in
various types of cancer32,33, and when expressed together with CD44
initiates metastasis18. We show that the CD44- and CD36-expressing
tumour cells only efficiently metastasize when using mitochondria as
an energy source. Disrupting mitochondrial responses by depleting
m5C is sufficient to reduce tumour cell dissemination. We show that
m5C and f5C levels in mt-tRNAMet are rate-limiting for the translation
of mitochondrially encoded subunits of the OXPHOS complex, thus
inhibiting the metabolic plasticity that is required for CD36-dependent
metastasis.
We further show that a mitochondria-driven gene signature has predictive value for patients with head and neck cancer. The expression
of genes that correlate with high levels of NSUN3—and therefore high
levels of m5C—predicted lymph node metastases and poor patient
prognosis. We propose that mitochondrial RNA-modifying enzymes
should be added to the growing list of RNA-modifying anticancer
602 | Nature | Vol 607 | 21 July 2022

drug targets. NSUN3 is a highly promising drug target because as a
stand-alone enzyme, it is solely responsible for mitochondrial m5C
formation.
A direct regulatory role for mitochondrial RNA modifications in
determining tumour cell behaviour is notable. Although mitochondrial
and cytosolic translation are known to be rapidly, dynamically and
synchronously regulated, it is widely assumed that cytosolic translation processes control mitochondrial translation unidirectionally34.
For example, invasive breast cancer cells rely on the transcription
coactivator PGC-1α (peroxisome proliferator-activated receptor-γ
coactivator-1α) to enhance oxidative phosphorylation and mitochondrial biogenesis to undergo metastasis35,36. However, it has become
increasingly clear that successful metastasis requires reversible metabolic changes that increase the cell’s capacity to withstand oxidative
stress37–39. Moreover, oxidative metabolism is sufficient to drive immortalization in Drosophila brain tumours40.
Certain antibiotics are used as adjuvant agents in the treatment
of cancers because of their anti-proliferative, pro-apoptotic or
anti-epithelial-to-mesenchymal transition capabilities, but their precise mode of action and effect on cancer therapies is controversial41.
Our study shows that distinct classes of antibiotics have specific effects
on tumours. Antibiotics that target mitochondrial translation inhibit
metastasis but do not affect tumour cell viability and growth. Similar to
our findings in head and neck cancer, several studies have repurposed
antibiotics to prevent OXPHOS-dependent ATP production and have
also shown that therapy resistance and tumour-initiating cells can be
eradicated by exposure to imatinib and/or tigecycline in leukaemia
and melanoma27,42–44.
Both treatment strategies—inhibition of mitochondrial translation
and targeting NSUN3—will, however, not target cancer cells specifically. Long-term systemic inhibition of mitochondrial translation will
have side effects. Patients who have a loss-of-function mutation in
the NSUN3 gene survive, yet present with combined mitochondrial
respiratory chain complex deficiency4. Antibiotics that target mitochondrial translation are often used in the long term and the side effects
are well-documented. However, we did not observe any reported side
effects in animals treated with the antibiotics, such as swelling of the
face or muzzle, skin rashes or diarrhoea.
Metastasis is the major cause of death in patients with cancer. Blocking the dissemination of tumour cells from primary tumours is one
approach to stop the successful colonization of tumour cells at distant
sites and thus prevent relapse. We propose that the inhibition of mitochondrial RNA modifications is a promising therapeutic opportunity to
stop the spread of cancer cells in later stages of tumour development.
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Methods
Cell lines and culture conditions
The squamous cell carcinoma cell lines SCC25 and FaDu were obtained
from ATCC (https://www.lgcstandards-atcc.org). The patient-derived
lines VDH01 and VDH15 were generated as described in a previous
report18. Patient samples to generate VDH01 and VDH15 were provided
by the Vall d’Hebron University Hospital Biobank (PT17/0015/0047)
integrated in the Spanish National Biobanks Network with written
informed consent from all participants. The samples were processed
following standard operating procedures with the appropriate approval
of the Ethical and Scientific Committees. The study followed the guidelines of the Declaration of Helsinki, and patient identity and pathological specimens remained anonymous in the context of the study.
All cells were cultured in a humidified incubator at 37 °C with 5% CO2.
SCC25 (ATCC CRL-168TM), FaDu (ATCC HTB-43), VDH01 and VDH15
cells were grown in keratinocyte serum-free medium (K-SFM, Gibco)
supplemented with 5 μg ml−1 penicillin–streptomycin, 0.025 mg ml−1
bovine pituitary extract and 0.2 μg ml−1 hEGF. FaDu (ATCCR HTB-43)
cells were grown in EMEM (LONZA) supplemented with 5 μg ml−1 penicillin–streptomycin and 10% fetal bovine serum (Gibco). LentiX 293T
cells grown in Dulbecco’s modified Eagle’s medium (DMEM) including
10% FBS were used for lentivirus production, after transfection with
Lipofectamine 2000 (Thermo Fisher Scientific), according to the
manufacturer’s instructions. All cells tested negative for mycoplasma
contamination.
NSUN3 shRNA plasmids were obtained from Dharmacon (SMART
vector; V3SVHS00_5546488: TTACAAATTCATGTCACCA and V3SVHS00_
7499725: TATAGAACAAACACCATCT). Site-directed mutagenesis to
generate the NSUN3-mutant construct was performed by mutating
the nucleotide 640 from T to G and the nucleotide 641 from G to C.
Full-length cDNA constructs for NSUN3 wild type (WT) or mutant (MUT)
in the pLenti-C-mGFP-P2A-Puro vector were obtained from OriGene.
VDH01 cells were transfected with the CD36 wild-type construct
CMV-mCherry-CD36-C-10 (#55011, Addgene) using Lipofectamine
2000 (Thermo Fisher Scientific) according to the manufacturer’s
instructions.
Cells in 2D or 3D culture were treated for 24 h with tigecycline
(Sigma-Aldrich, 10 µM), doxycycline (Sigma-Aldrich, 10 µg ml−1),
linezolid (Sigma-Aldrich, 45 µM), chloramphenicol (Sigma-Aldrich,
300 µg ml−1), amoxicillin (Sigma-Aldrich, 10 µg ml−1) and ampicillin
(Sigma-Aldrich, 10 µg ml−1).
fCAB and bisulfite sequencing and analyses
Total RNA was isolated from OSCC cells using Trizol, according to the
manufacturer’s instructions (Thermo Fisher Scientific) and DNase
treated. For detection of m5C and f5C in mitochondrial tRNAs, tRNA
from total RNA was isolated using the Mirvana kit, as described by the
manufacturer (Thermo Fisher Scientific). O-ethylhydroxylhamine
and bisulfite treatment, library preparation and sequencing were performed as previously described14.
For targeted gene-specific bisulfite sequencing, RNA isolation,
bisulfite conversion reaction and sequencing, approximately 1–2 μg
of RNA samples was used45. For identification of f5C modification, the
RNA was pre-exposed to 10 mM of O-ethylhydroxylamine in 100 mM
MES buffer (pH 5.0), for 2 h at 37 °C, followed by bisulfite treatment. For
m5C, the RNA was bisulfite-treated by mixing with 42.5 μl 40% sodium
bisulfite solution (pH 5.0) and 17.5 μl DNA protection buffer supplied
with the EpiTect Bisulfite Kit (Qiagen). The reaction mixture was then
incubated for three cycles of 5 min at 70 °C, followed by 1 h at 60 °C
on a thermal cycler. To desalt the reaction, all samples were passaged
through Micro Bio-Spin 6 chromatography columns, following the
manufacturer’s instructions (Bio-Rad). The samples were then desulfonated by adding an equal volume of 1 M Tris (pH 9.0) to the reaction
mixture and incubating for 1 h at 37 °C. Bisulfite-treated RNA samples

were then precipitated overnight with 2.5 volumes of 100% ethanol, 0.1
volumes of 3 M sodium acetate (pH 5.5) and 1–2 μl Glycoblue (AM9516;
Ambion) at −80 °C. For cDNA synthesis, reverse transcription reactions were carried out with the SuperScript III Reverse Transcriptase
kit (Thermo Fisher Scientific), following the manufacturer’s instructions. Five hundred nanograms of bisulfite-converted RNA was used.
A gene-specific primer (Fw: AGTAAGGTTAGTTAAATAAGTT) was used
in the reverse transcription reaction.
The cDNA was PCR-amplified using primers specific for deaminated sequences (Fw: AGTAAGGTTAGTTAAATAAGTT, Rv: TAATACAA
AAAAAATATAACCA). The PCR products were separated from unincorporated primers using low-melting agarose gels using a Gel Extraction
Kit (Qiagen) for products in between 50 and 90 bp (amplicon at ±70 bp).
Illumina sequencing libraries from the converted tRNA amplicons
were generated using the NEBNext Ultra II DNA Library Prep Kit (NEB,
#E7645) and indexed using the Multiplex Oligos for Illumina Index
Primers Set 1 (NEB, E7335). To enable sequencing of the low-complexity
tRNA libraries the final equimolar tRNA amplicon pool was multiplexed
in a 1:1 volume ratio with a high-complexity library generated from
fragmented human gDNA and sequenced on a MiSeq v2 using the Nano
kit in PE100 bp mode.
Raw sequencing fastq files were trimmed with ‘TrimGalore!’ of the
adapter, retaining only reads with a minimum length of 25 nt. Reads
were aligned to the GRCh38 (hg38) reference genome using Bismark
(v.0.22.3) with the ‘--non_directional’ option and default parameters.
mtRNA genomic coordinates for the GRCh38 reference genome were
obtained from the ENSEMBL database. Original targeted sequencing
reads and their multiple sequence alignments on mtRNAs were
extracted from sorted Bismark alignment (bam) files using the R
packages RSamtools and GenomicAlignments. Multiple sequence
alignments and heat maps were generated with ‘matrixplot’ from the
R package VIM.

Protein extraction and western blotting
Cells were first rinsed twice with PBS and lysed in ice-cold RIPA buffer
(50 mM Tris-HCl (pH 7.4), 1% NP-40, 150 mM NaCl, 0.1% SDS and 0.5%
sodium deoxycholate per ml RIPA per T-75 or 100 mm culture dish). RIPA
was supplemented with complete Mini EDTA-free Protease Inhibitor
Cocktail tablets (Roche), and cells were collected using a cell scraper.
The lysates were centrifuged and their supernatant collected and kept
on ice. The concentration of each protein sample was assessed using the
Pierce BCA Protein Assay kit (Thermo Fisher Scientific) according to the
manufacturer’s instructions and measured using a spectrophotometer.
Cell protein lysates were mixed with Laemmli buffer (2×) and run
on separating polyacrylamide gels and transferred to a nitrocellulose
or PVDF membrane (GE Healthcare). Membranes were blocked for a
minimum of 1 h at room temperature in 5% (w/v) non-fat milk 10% (w/v)
in 1× TBS and 0.1% Tween-20 (TBS-T) (48.4 g Tris Base, 160 g NaCl, and
H2O to 1 L; for 20× TBS buffer at adjusted pH 7.6) and incubated with
the primary antibody in blocking solution overnight at 4 °C. Each membrane was washed three times for 10 min in TBS-T before incubation
with the appropriate horseradish peroxidase (HRP)-labelled secondary
antibody (1:10,000) in TBS-T at room temperature for 1 h (anti-mouse
NA931 and anti-rabbit IgG HRP; Millipore). Finally, the membranes were
washed as before and the antibodies were detected by using the Amersham ECL Prime Western Blotting Detection Reagent (GE Healthcare).
The primary antibodies used were NSUN3 (1:500, GTX46175, GenTex),
MTCO1 (1:1,000, ab91317, Abcam), MTCO2 (1:1,000, PA5-26688, Thermo
Fisher Scientific) and HSP90 (1:1,000, sc-13119, Santa Cruz).
RNA isolation and RT–qPCR
Total RNA was prepared using Trizol (Thermo Fisher Scientific) and
further purified using TURBO DNase treatment (Thermo Fisher Scientific) according to the manufacturer’s instructions. Double-stranded
cDNA was synthesized from 1 μg of RNA using Superscript III reverse

transcriptase (Thermo Fisher Scientific), following the manufacturer’s
instructions with Random Primers (Promega). Each RT–qPCR reaction
was set up using predesigned probes: NSUN3, ALKBH1, CD44, CD36 or
keratin 10 probes (Hs00222961_m1, Hs00195696_m1, Hs01075864_
m1, Hs00354519_m1, Hs00166289_m1). A human 18S rRNA probe
(Hs99999901_s1) was used for normalization using the ΔCt method.
RT–qPCR and data acquisition were conducted using the QuantStudio
qPCR machine (Applied Biosystems).

Mitochondrial DNA copy number and ROS determination
Total cellular DNA was isolated from OSCC cells using the DNeasy Blood
and Tissue kit (Qiagen) according to the manufacturer’s instructions.
Mitochondrial DNA copy number was determined by qPCR using a
mtDNA monitoring primer set kit (7246, Takara).
For measurement of mitochondrial ROS levels, MitoSOX was used
according to the manufacturer’s instructions. In brief, culture cells were
incubated with MitoSOX reagent (2 µM; Thermo Fisher Scientific) for
30 min at 37 °C. After incubation, cells were washed twice and resuspended in PBS. The fluorescence of each sample was measured by the
BD LSRFortessa Analyzer (BD Biosciences). Data were further processed
by FlowJo software. Fluorescence measurements were visualized by
histogram, and the raw fluorescence median values were extracted
for quantification.
Analysis of mitochondrial protein synthesis
To investigate protein synthesis, OSCC cells were treated with OP-puro
as previously described46,47. Reconstituted OP-puro (50 μM; 10 mM
reconstituted stock (pH 6.4); Medchem Source) was added to cultured cells 30 min before collection. For measuring mitochondrial
protein synthesis, MitoTracker Deep Red was added together with
OP-puro 30 min before collection at a concentration of 200 nM in
the culture medium (Thermo Fisher Scientific). An untreated sample
served as a negative control in each assay. Cycloheximide (50 μg ml−1;
Sigma-Aldrich) or puromycin (2 μg ml−1; Sigma-Aldrich) treated cells
served as positive controls. Cells were rinsed with PBS and then collected with trypsin-EDTA.
For mitochondrial protein synthesis, mitochondria were extracted
following the instructions of the manufacturer of the mitochondria
isolation kit (Thermo Fisher Scientific). The extracted organelles were
then fixed in 0.5 ml PFA (1% w/v in PBS; Santa Cruz) and kept for 15 min
on ice in the dark. After fixation, all samples were washed in PBS and
permeabilized in PBS supplemented with 3% FBS and 0.1% saponin
(Sigma-Aldrich) for 5 min at room temperature. To conjugate OP-puro
to a fluorochrome, an azide-alkyne cycloaddition was performed for
30 min at room temperature in the dark. For this, the Click-iT Cell
Reaction Buffer Kit (Thermo Fisher Scientific) and 5 μM of Alexa Fluor
488/647-Azide (Thermo Fisher Scientific) were used. To remove excess
reagents and reduce the background signal, the cells were washed twice
in PBS supplemented with 3% FBS and 0.1% saponin. Finally, all samples
were resuspended in PBS and analysed by flow cytometer (Fortessa).
Fluorescence of each sample was measured by the BD LSRFortessa
Analyzer (BD Biosciences). Data were further processed by FlowJo software. Fluorescence measurements were visualized by histogram, and
the raw fluorescence median values were extracted from the selected
subpopulations.
To assess the effect of antibiotics on mitochondrial protein synthesis, cells were treated with tigecycline (Sigma-Aldrich, 10 µM),
doxycycline (Sigma-Aldrich, 10 µg ml−1), linezolid (Sigma-Aldrich,
45 µM), chloramphenicol (Sigma-Aldrich, 300 µg ml−1), amoxicillin
(Sigma-Aldrich, 10 µg ml−1) and ampicillin (Sigma-Aldrich, 10 µg ml−1)
24 h before OP-puro incorporation.
Flow cytometry and analysis
Cells were trypsinized, washed twice with PBS and fixed for 10 min with
1% paraformaldehyde in PBS. After two additional PBS washes, cells

were incubated with combinations of antibodies: PE–Cy7-conjugated
CD44 (1:300, BD Pharmingen, 560533), FITC- or eFluor 660- conjugated
CD36 (1:500, BD Bioscience, 555454 and 50-0369-42, Thermo Fisher
Scientific). After incubation for 45 min at 4 °C, cells were washed twice
in PBS. Data acquisition was performed on a BD LSRFortessa Analyzer
or a cell sorter (BD Biosciences). Data were analysed by FlowJo software.

Cell death assay
Cell death was measured by flow cytometry (fluorescence-activated
cell sorting; FACS) analysis of DNA fragmentation using propidium
iodide (PI) and Annexin V staining (BD Biosciences). In brief, the supernatant and trypsinized cells were collected and centrifuged for 5 min at
1,800 rpm at 4 °C. Pellets were resuspended in a binding buffer containing 50 μg ml−1 propidium iodide and Annexin V for 15 min at 4 °C. Cells
were analysed by FACS within 1 h after staining. Cells were labelled as
follow: live cells are PI− and Annexin V−; early apoptosis cells are PI− and
Annexin V+; late apoptosis cells are PI+ and Annexin V+; and necrotic
cells are PI+ and Annexin V−.
For analysis of cell death in the CD44HCD36H subpopulation, SCC25
cells were infected with the lentivirus containing the GFP-shRNA targeting NSUN3. At day 0, 2, 4 and 6 after viral infection, the supernatant and trypsinized cells were collected and stained for 45 min with
PE–Cy7-conjugated CD44 (1:300, BD Pharmingen, 560533) and eFluor
660- conjugated CD36 (1:300, 50-0369-42, Thermo Fisher Scientific).
Cells were then washed and stained for 15 min with PI and Annexin V
(BD Biosciences) according to the manufacturer’s instructions. The
double-negative population (PI−Annexin V−) was labelled as the live
cells. For all cell death assays data are represented as mean ± s.d. of at
least three independent experiments carried out in triplicate.
Oxygen consumption, lactate production and ATP rate assay
Oxygen consumption rate (OCR) and extracellular acidification rate
(ECAR) were measured on a Seahorse XFe96 extracellular flux analyzer
(Agilent) following the manufacturer’s instructions. In brief, cells were
seeded at 1 × 105 (SCC25, VDH15) or 5 × 104 (FaDu) cells per well in cell
culture microplates (Sigma-Aldrich). After reaching 70–90% confluency, cells were equilibrated for 1 h in XF assay medium supplemented
with 10 mM glucose, 1 mM sodium pyruvate and 2 mM glutamine in a
non-CO2 incubator. OCR and ECAR were monitored at baseline and
throughout sequential injections of oligomycin (1 μM), carbonyl
cyanide-4-(trifluoromethoxy)phenylhydrazone (1 μM) and rotenone
or antimycin A (0.5 μM each). For measurement of ATP rate assay, only
oligomycin (1 µM), followed by rotenone or antimycin A (0.5 µM each)
was used. Data for each well were normalized to protein concentration
as determined using the Pierce BCA Protein Assay kit (Thermo Fisher
Scientific) after measurement on the XFe96 machine.
Analysis of metabolites through ultra-high performance liquid
chromatography–mass spectrometry
For determination of organic acids, three million cells per sample were
extracted in 0.2 ml ice-cold methanol with sonication on ice. Fifty microlitres of extract was mixed with 25 µl 140 mM 3-nitrophenylhydrazine
hydrochloride (Sigma-Aldrich), 25 µl methanol and 100 µl 50 mM
ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride
(Sigma-Aldrich) and incubated for 20 min at 60 °C. Separation was performed on the above-described ultra-high performance liquid chromatography (UPLC) system coupled to a QDa mass detector (Waters) using
an Acquity HSS T3 column (100 mm × 2.1 mm, 1.8 µm, Waters) which was
heated to 40 °C. Separation of derivates was achieved by increasing the
concentration of 0.1 % formic acid in acetonitrile (ACN; B) in 0.1 % formic
acid in water (A) at 0.55 ml min−1 as follows: 2 min 15% B, 2.01 min 31% B,
5 min 54% B, 5.01 min 90% B, hold for 2 min, and return to 15% B in 2 min.
Mass signals for the following compounds were detected in single-ion
record (SIR) mode using negative detector polarity and 0.8 kV capillary
voltage: lactate (224.3 m/z; 25 V cone voltage (CV)), malate (403.3 m/z;
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25 V CV), succinate (387.3 m/z; 25 V CV), fumarate (385.3 m/z; 30 V CV),
citrate (443.3 m/z; 10 V CV), 2-hydroxy-ketoglutarate (417.0 m/z; 15 V
CV), pyruvate (357.3 m/z; 15 V CV) and ketoglutarate (550.2 m/z; 25 V CV).
Data acquisition and processing were performed with the Empower3
software suite (Waters). Organic acids were quantified using ultrapure
standards (Sigma).

Orthotopic transplantation of OSCC cells
All mice were housed in the DKFZ Central Animal Laboratory. All mouse
husbandry and experiments were performed according to the guidelines of the local ethics committee under the terms and conditions of
the animal licence G-351/19.
OSCC cells were transduced with a retroviral vector expressing
luciferase-GFP (luc-GFP). A total of 75,000 cells were injected into
the tongue of NSG mice18. Adult male and female mice were used but
sex-matched in each experiment. The progress of cancer development was monitored for 21 days and luciferase signal was measured in
the oropharyngeal area, the surrounding lymph nodes and the lungs.
Luciferase bioluminescent signal was measured immediately after
injection (T0) and then, at least once weekly using the Xenogen IVIS
Imaging System-100 (Caliper Life Sciences). For this, mice received
intraperitoneal injection of 50 μl d-luciferin (Promega; 5 mg ml−1 in
PBS). Continuous administration of isofluorane gas was provided to
maintain the anaesthesia of the mice during imaging. Data were quantified with Living Image software v.4.4 (Caliper Life Sciences). Quantifications were calculated with unsaturated pixels. The minimum and
maximum values of the colour scales are shown in the images.
To assess the effect of antibiotics on tumour development, the SCC25
cell line and VDH01 PDC were injected in the tongue of NSG mice. After
7 days, we daily injected 100 µl of tigecycline (Sigma-Aldrich, 50 mg kg−1),
doxycycline (Sigma-Aldrich, 50 mg kg−1), amoxicillin (Sigma-Aldrich,
50 mg kg−1) or PBS as a control.
The tumour growth was monitored using in vivo imaging (Xenogen
IVIS Imaging System-100; Caliper Life Sciences) once in the first week
and then two to three times per week for a maximum of four weeks.
Mice were killed before this time point when the tumour reached a
maximum diameter of 1.0 cm. None of the mice in this study reached
this end-point. Experiments were also stopped immediately when mice
showed a hunched posture or weight loss of 20% of their initial weight.
Mice with tumours were also killed if they showed signs of necrosis or
inflammation associated with tumour growth. Mice with moderate
dyspnoea owing to metastases in the lungs were killed. Mice with signs
of infection, non-healing, bloody or oozing wounds were also killed.
These limits were not exceeded in any of the experiments. For each
experiment, mice were killed at the same time, once one experimental
group reached the humane end-point.
Isolation of orthotopic tumour cells
Tumours were separated from mouse tongue tissue and the tissue
was chopped in 0.5% trypsin 1-300 (MP Biomedical) in K-SFM medium
(Gibco). After complete homogenization, samples were incubated at
37 °C for 2 h with shaking. Homogenates were filtered sequentially in
40-μm BD strainers and centrifuged at 1,000 rpm for 10 min at 4 °C.
The supernatant was discarded, and each pellet was resuspended in
1× PBS/4% calcium-chelated FBS for antibody staining and subsequent
FACS analysis.
Tumoroid assays
Cells cultured in 2D were resuspended in K-SFM medium (Thermo
Fisher Scientific) and placed in an ultra-low adherent culture dish
(STEMCELL Technologies). After 7 days, the number of tumoroids
per well was assessed and representative pictures were taken for each
condition. For the invasion assay, tumoroids were pelleted (200g, 5 min)
and grown in the 3D collagen I culture kit (EMD Millipore) for 24 or
48 h. Images of tumoroids were taken using a Leica DMIL microscope.

Quantification of the number of leader cell was done on tumoroids
from three independent experiments.
To overexpress CD36, 5 days after seeding 2D cells in an ultra-low
adherent culture dish, tumoroids were transiently transfected with
CMV-mCherry-CD36-C-10 (55011, Addgene). Tumoroids were washed
after 12 h and reseeded in an ultra-low adherent culture dish with 30 µM
of palmitate-BSA (Agilent, 102720-100). After 24 h, tumoroids were
pelleted and casted in a collagen I culture kit for 48 h.
To assess the effect of antibiotics on tumoroid invasion, tigecycline
(Sigma-Aldrich, 10 µM), doxycycline (Sigma-Aldrich, 10 µg ml−1), linezolid (Sigma-Aldrich, 45 µM), chloramphenicol (Sigma-Aldrich,
300 µg ml−1), amoxicillin (Sigma-Aldrich, 10 µg ml−1) and ampicillin
(Sigma-Aldrich, 10 µg ml−1) were added to the medium directly after
seeding the tumoroids in the 3D collagen gel.

Immunostaining
Extracted mouse tongues containing the tumours were fixed overnight
with 4% paraformaldehyde, transferred to 70% ethanol and embedded in paraffin. Samples were sectioned at 4 μm. Sections were permeabilized for 10 min with PBS containing 0.3% Triton X-100 at room
temperature and washed three times for 5 min in PBS. To block nonspecific antibody binding, sections were incubated with blocking buffer
comprising 3% FBS in PBS with 0.1% Tween-20 (PBST) for 1 h. To detect
specific proteins of interest, cells were then incubated with primary
antibodies diluted in 1% FBS in PBST at 4 °C overnight. The cells were
then washed three times in PBS for 5 min each. To label the detected proteins, cells were incubated with the Alexa Fluor 488-, Alexa Fluor 555-,
Alexa Fluor 647-conjugated secondary antibodies diluted in 1% BSA
in PBST for 1 h at room temperature, protected from light (1:1,000;
Thermo Fisher Scientific). Sections were washed as before and their
nuclei were counterstained with DAPI (1:10,000 in PBS; Sigma-Aldrich)
for 10 min. Finally, sections were rinsed with PBS and the glass coverslips were mounted using fluorescence mounting medium (S302380-2;
Agilent). The primary antibodies used were CD44 (1:200, 14-0441-82,
Thermo Fisher Scientific), MTCO1 (1:200, ab91317, Abcam), MTCO2
(1:200, PA5-26688, Thermo Fisher Scientific), cytokeratin 10 (1:200,
PRB-159P, Biolegend), and filaggrin (1:200, Covance, PRB-417P-100).
Tumoroids were incubated for 2 h with MitoTracker Red CMXROS
(Thermo Fisher Scientific). Then, they were fixed 15 min with 4% paraformaldehyde, washed three times in PBS and counterstained with
DAPI (1:10,000 in PBS) for 10 min.
Cells infected with GFP-NSUN3-WT or GFP-NSUN3-MUT constructs
were incubated for 30 min with MitoTracker Deep Red (Thermo Fisher
Scientific) at 200 nM. Then, they were fixed for 15 min with 1% paraformaldehyde, washed three times in PBS and mounted with a fluorescent
mounting medium (Dako). Fluorescence images were acquired using
a confocal microscope (Leica SP5) at 1,024 × 1,024-dpi resolution. The
length of mitochondria was analysed with Fiji software by taking the
average length of 20 mitochondria per cell in different conditions.
To measure mitochondrial length in invading leader cells, tumoroids
were casted in collagen I matrix for 48 h. Then, they were fixed for 15 min
with 4% paraformaldehyde, washed three times in PBS and incubated
at room temperature in 30% sucrose PBS for 12 h, followed by 2 h in
OCT–30% sucrose PBS (1:1). Collagen matrix was embedded and frozen
in OCT and sectioned at 10 µm. Sections were permeabilized for 10 min
with PBS containing 0.3% Triton X-100 at room temperature and washed
three times for 5 min in PBS. To block nonspecific antibody binding,
sections were incubated with blocking buffer comprising 3% FBS in PBS
with 0.1% Triton X-100 for 1 h. To detect specific proteins of interest,
cells were then incubated with primary antibodies diluted in 1% FBS in
PBST at 4 °C overnight. The cells were then washed three times in PBS
for 5 min each. To label the detected proteins, cells were incubated
with Alexa Fluor 647-conjugated secondary antibodies diluted in 1%
BSA in PBST for 1 h at room temperature, protected from light (1:1,000;
Thermo Fisher Scientific). Sections were washed as before and their

nuclei counterstained with DAPI (1:10,000 in PBS; Sigma-Aldrich) and
Alexa-555 Phalloidin (Thermo Fisher Scientific) for 10 min. Finally,
sections were rinsed with PBS and the glass coverslips were mounted
using fluorescence mounting medium (S302380-2; Agilent). The primary antibody used was TOMM20 (1:300, Abcam, ab56783). Fluorescence images were acquired using a confocal microscope (Leica SP5) at
1,024 × 1,024-dpi resolution. All of the images were further processed
with Fiji software. Mitochondrial length was measured in pixels for at
least 20 mitochondria per cell, with a minimum of 15 cells per condition
from 3 independent experiments.
For glucose uptake, tumoroids were cultured for 7 days in nonadherent plates (STEMCELL Technologies). The medium was changed
for DMEM no glucose (Thermo Fisher Scientific) for 30 min. Then,
tumoroids were treated for 3 h with 50 µM 2-deoxy-d-glucose-IR (Licor).
Tumoroids were washed three times in PBS and fixed with 4% paraformaldehyde for 15 min. After washing, tumoroids were labelled with DAPI
(1:10,000 in PBS) and F-actin counterstained with Alexa-647 Phalloidin (Thermo Fisher Scientific) for 30 min. Fluorescence images were
acquired using a confocal microscope (Leica SP5) at 1,024 × 1,024-dpi
resolution. All of the images were further processed with Fiji software.
Immunohistochemistry for NSUN3 was performed as described previously24. Patients of the HIPO-HNC cohort (GSE117973) were treated
between 2012 and 2016 at the University Hospital Heidelberg, Germany.
Patient samples were obtained and analysed under protocols S-206/2011
and S-220/2016, approved by the Ethics Committee of Heidelberg
University, with written informed consent from all participants. This
study was conducted in accordance with the Declaration of Helsinki.
Formalin-fixed paraffin-embedded (FFPE) tumour sections were
labelled for NSUN3 (1:100; Genetex, GTX46175). The specificity of antibody staining was confirmed by immunohistochemistry staining using
a rabbit IgG isotype control antibody (1:1,000; DA1E, Cell Signaling
Technology) on serial FFPE tissue sections from HNSCC samples. The
NSUN3 immunoscore (IRS, ranging from 0 to 300) was calculated as a
product of staining intensity (ranging from low = 1, moderate = 2 and
high = 3) and the percentage total of positively stained tumour cells
(ranging from 0% to 100%). FFPE tumour sections were provided by
the tissue bank of the National Center for Tumour Disease (Institute of
Pathology, University Hospital Heidelberg, Germany), at which preservation and storage of tumour samples occurs under controlled and
standardized protocols (https://www.klinikum.uni-heidelberg.de/
pathologie-kooperationen/nct-gewebebank).
To estimate the relative distance of cell populations from the
tumour–stroma border, pixels were classified as NSUN3+ or NSUN3−
(ref. 48). For each NSUN3+ or NSUN3− pixel we then identified the nearest
neighbouring tumour–stroma border. Using Fiji software, we calculated the Euclidian distance map. Cell counts were then pooled into
50 µm bins.

Electron microscopy
Cells grown on punched sheets of Aklar-Fluoropolymer films (EMS)
were embedded in epoxy resin for ultrathin sectioning according to
standard procedures: primary fixation in buffered aldehyde (4% formaldehyde, 2% glutaraldehyde, 1 mM CaCl2, 1 mM MgCl2 in 100 mM sodium
phosphate, pH 7.2), post-fixation in buffered 1% osmium tetroxide
followed by en-bloc staining in 1% uranylacetate. After dehydration
in graded steps of ethanol, the adherent cells were flat-embedded
in epoxide (Glycidether, NMA, DDSA: SERVA). Ultrathin sections at a
nominal thickness of 60 nm and contrast-stained with lead citrate and
uranylacetate were observed in a Zeiss EM 910 at 120 kV (Carl Zeiss) and
micrographs were taken using a slow scan CCD camera (TRS).
Quantitative translation measurements using mass
spectrometry and analyses
Multiplexed enhanced protein dynamics (mePROD) proteomics followed by mass spectrometry were performed as previously described23.

In brief, cell pellets from sorted cell populations or bulk were lysed in
2% SDS, 150 mM NaCl, 10 mM TCEP, 40 mM chloracetamide and 100 mM
Tris pH 8. Lysates were incubated at 95 °C, followed by sonification
and additional incubation at 95 °C for 10 min. Proteins were isolated
using methanol-chloroform precipitation and resuspended in 8 M
urea and 10 mM EPPS pH 8.2. Digests were performed overnight after
dilution to 1 M urea, 10 mM EPPS pH 8.2 with 1:50 w/w LysC (Wako) and
1:100 w/w trypsin (Promega). Peptides were isolated using tC18 SepPak
columns (50 mg, Waters) and subsequently dried. For TMT labelling,
peptides were resuspended in 200 mM EPPS pH 8.2 and 10% ACN and
mixed 1:2 (w/w) with TMT reagents. For mePROD baseline and boost,
completely light and heavy digests were used as described previously.
Peptides were fractionated using a Dionex Ultimate 3000 analytical
HPLC. Pooled and purified TMT-labelled samples were resuspended
in 10 mM ammonium bicarbonate (ABC) and 5% ACN, and separated
on a 250-mm-long C18 column (X-Bridge, 4.6 mm ID, 3.5 µm particle
size; Waters) using a multistep gradient from 100% solvent A (5% ACN
and 10 mM ABC in water) to 60% solvent B (90% ACN and 10 mM ABC
in water) over 70 min. Eluting peptides were collected every 45 s into a
total of 96 fractions, which were cross-concatenated into 24 fractions
and dried for further processing.
Peptides were resuspended in 2% ACN and 0.1% TFA and separated on
an Easy nLC 1200 (Thermo Fisher Scientific) and a 35-cm-long, 75-µm
ID fused-silica column, which had been packed in house with 1.9-µm
C18 particles (ReproSil-Pur, Dr. Maisch), and kept at 45 °C using an integrated column oven (Sonation). Peptides were eluted by a non-linear
gradient from 5% to 38% ACN over 120 min and directly sprayed into a
QExactive HF mass spectrometer equipped with a nanoFlex ion source
(Thermo Fisher Scientific) at a spray voltage of 2.3 kV. Full scan MS spectra (350-1400 m/z) were acquired at a resolution of 120,000 at m/z 200,
a maximum injection time of 100 ms and an AGC target value of 3 × 106.
Up to 20 most intense peptides per full scan were isolated using a 1 Th
window and fragmented using higher energy collisional dissociation
(normalized collision energy of 35). MS/MS spectra were acquired with
a resolution of 45,000 at m/z 200, a maximum injection time of 86 ms
and an AGC target value of 1 × 105. Ions with charge states of 1 and >6
as well as ions with unassigned charge states were not considered for
fragmentation. Dynamic exclusion was set to 20 s to minimize repeated
sequencing of already acquired precursors.
Raw files were analysed using Proteome Discoverer (PD) 2.4 software
(Thermo Fisher Scientific). Spectra were selected using default settings and database searches were performed using Sequest HT node
in PD. Database searches were performed against the trypsin-digested
Homo Sapiens SwissProt database (2018-11-21) and FASTA files of common contaminants (‘contaminants.fasta’ provided with MaxQuant) for
quality control. Fixed modifications were set as TMT6 at the N terminus
and carbamidomethyl at cysteine residues. One search node was set up
to search with TMT6 (K) and methionine oxidation as static modifications to search for light peptides and one search node was set up with
TMT6+K8 (K, +237.177), Arg10 (R, +10.008) and methionine oxidation as
static modifications to identify heavy peptides. For both nodes, Acetyl
(+42.011), Met-loss (−131.040) and Met-loss + Acetyl (−89.030) were set
as dynamic modifications at the protein terminus. Searches were performed using Sequest HT. After searching, posterior error probabilities
were calculated and peptide-spectrum matches (PSMs) filtered using
Percolator with default settings. The consensus workflow for reporter
ion quantification was performed with default settings, except that the
minimum signal-to-noise ratio was set to 5. Results were then exported
to Excel files for further processing by an in-house Python pipeline23,49.
For co-expression clustering, a type II ANOVA was used on a fitted ordinary least squares linear model for each protein to filter out
high-variance proteins. All proteins with an ANOVA P value of less
than 0.05 were used for further analysis. The remaining data were
log2-transformed and a Pearson correlation matrix was calculated.
ToppGene was used for the GO analysis on the clusters.
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RNA-seq and analyses
Tumours were isolated from mice, and connective tissue was removed
to the largest extent possible. Tissue was chopped in 0.5% trypsin 1-300
(MP Biomedical) in K-SFM medium (Gibco) using a McIlwain Tissue
Chopper. After complete homogenization, samples were incubated at
37 °C for 90 min with shaking. Homogenates were filtered sequentially
in 100-μm, 70-μm and 40-μm BD strainers and centrifuged at 1,000 rpm
for 10 min at 4 °C. Supernatant was discarded, and each pellet was
resuspended in 1× PBS/4% calcium-chelated FBS. GFP-positive human
cancer cells were flow-sorted. Total RNA was extracted using the Trizol
protocol and treated with DNase. rRNA-depleted RNA was used to generate the RNA-seq libraries using NEXTflex Directional RNA-seq Kit V2
(Illumina). All 11 samples were multiplexed and sequenced in the HiSeq
4k PE 100 sequencing platform (Illumina).
For all samples, low-quality bases were removed with the Fastq_quality_
filter from the FASTX Toolkit (0.0.13) with 90% of the read needing
a quality phred score > 20. Homertools 4.7 was used for PolyA-tail
trimming, and reads with a length < 17 were removed. Genomic mapping was performed with STAR v.2.3 for the filtered reads with human
genome 38 (ref. 50). For quality checking, PicardTools 1.78 CollectRNASeqMetrics was performed on the mapped reads. Count data were generated by FeatureCounts v.1.4.5-p1 with parameters --minReadOverlap
3 -T 3 -M -O -s 0 using the gencode.v32.annotation.gtf (https://www.
gencodegenes.org/) file for annotation51. The FPKM values were calculated using the same annotation file with a custom perl script. For the
comparison with DESeq252, the input tables containing the replicates
for the groups to compare were created by a custom perl script. In the
count matrix, rows with an average count number of less than 10 were
removed, then DESeq2 (v.1.4.1) was run with default parameters.
The result tables were annotated with gene information (gene symbol,
gene type) derived from the gencode.v32.annotation.gtf file.
In silico analyses using TCGA-HNSC datasets
RNA expression levels, clinical as well as follow-up data were downloaded from the TCGA-HNSC (n = 500) cohort (https://portal.gdc.
cancer.gov/) in November 2019. Differentially expressed gene analysis was performed by the ‘EdgeR’ package in R (ref. 53), depending on
NSUN3 expression with a cut-off at false discovery rate (FDR) < 0.01 and
a log2-transformed fold change either higher than 1 or lower than −1. The
GSEA algorithm was used to compute the normalized enrichment score
and statistical significance for Molecular Signatures Database (MSigDB)
hallmark, C2, C5 and C6 collection terms and gene set permutations
were performed 1,000 times for each analysis by GSEA v.4.0.3 software.
For clustering analysis, expression values of the top and bottom 50
differentially expressed genes of NSUN3 quartile expression depending
on the log2-transformed fold change were ln(x + 1) transformed, and
clustering of patients from the TCGA was performed using Euclidean
distance and Ward (unsquared distances) linkage. Heat maps with
hierarchical trees were generated by the web tool ClustVis54.
Differentially expressed gene analysis was performed on VDH15
control and shNSUN3 tumours, with a cut-off at FDR < 0.01. Enrichment
scores were computed by ssGSEA applying the ‘GSVA’ package in R55,
using the top and bottom 150 differentially expressed genes. ssGSEA
scores of patients from the TCGA were then plotted with regard to the
occurrence of lymph node metastasis.
To identify the NSUN3-driven gene signature in progression events,
the best cut-off of the top or bottom 150 NSUN3-related signature
ssGSEA scores for progression-free interval (PFI) was computed
by ‘maxstat’ (smethod= “LogRank”, pmethod= “exactGauss”, and
abseps=0.01) in the TCGA-HNSC cohort. We defined the patients in
the HNSC cohort whose top 150 ssGSEA score was higher than the best
cut-off and whose bottom 150 ssGSEA score was lower than the best
cut-off as the high NSUN3-driven signature group. On the other side, the
patients in the HNSC cohort whose top 150 ssGSEA score was lower than

the best cut-off and whose bottom 150 ssGSEA score was higher than
the best cut-off were defined as the low NSUN3-driven signature group.

Sample sizing and collection
No statistical methods were used to predetermine sample size, but
a minimum of three samples were used per experimental group and
condition. The number of samples is represented in the graphs as
one dot per sample. Samples and experimental mice were randomly
assigned to experimental groups. Sample collection was also assigned
randomly. Sample collection and data analysis were performed blindly
whenever possible. Whenever possible automated quantifications were
performed using the appropriate software.
Reporting summary
Further information on research design is available in the Nature
Research Reporting Summary linked to this paper.

Data availability
Quantitative proteomics data are available at the Proteomics Identifications Database (PRIDE) with accession number PXD021835.
RNA-seq data using VDH01 and VDH15 cells are available at the European Genome-phenome Archive (EGA) under the accession number
EGAS00001004765, including the attached studies EGAD00001008743
and EGAD00001008742. All other sequencing data are deposited at
the Gene Expression Omnibus (GEO) under the accession number
GSE201993. Results are in part based on TCGA-HNSC data (accession
number phs000178) that were downloaded from TCGA (https://portal.
gdc.cancer.gov). Source data are provided with this paper.
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Extended Data Fig. 1 | See next page for caption.

Extended Data Fig. 1 | Depletion of NSUN3 removes m5C and f5C from
mt-tRNA Met . a. Schematic representation of fCAB- and bisulfite (BS) parallel
sequencing (seq). b. Detection of m5C and f5C sites in the mitochondrial (mt)
tRNA landscape using fCAB-Seq in normal human epithelial keratinocytes
(NHEK). Plotted are all cytosines on the mitochondrial chromosome (ChrM)
with a coverage >100 in both independent replicates. The two peaks
correspond to C34 of mt-tRNAMet mediated by NSUN3 and C47, 48, 49 in
mt-tRNASer2 mediated by NSUN2 respectively. c. Heat map comparing
modification levels along ChrM in three independent cell lines. d. mt-tRNASer2
secondary structure with known modifications highlighted in red. e. Relative
fold change (FC) of NSUN3 RNA levels in the indicated cell lines infected with
control (Ctr) or NSUN3 shRNAs (sh#1, sh#2) (n = 3 independent infections).
f. Sequence of bisulfite-converted mt-tRNAMet. g. m5C levels in the indicated

cell lines shown in (h). h. Illustration of mt-tRNAMet in the anticodon loop (upper
panel), and heat maps (lower panels) showing methylated (blue) and nonmethylated (grey) cytosines identified by RNA BS-seq in the indicated cell lines
expressing (shRNA ctr) or lacking NSUN3 (shRNA NSUN3). i,j. Log 2 FC of NSUN3
(red) and ALKBH1 (grey) RNA levels in the indicated cell lines versus NHEK cells
(i) (n = 3 independent infections) or after depletion of NSUN3 in time course
(j) (n = 3 technical replicates per time point). k. Correlation of NSUN3 and
ALKBH1 protein levels in cancer cell lines (Cancer Cell Line Encyclopedia).
l,m. Correlation of ALKBH1 and NSUN3 RNA levels in normal oesophagus
mucosa and TCGA normal oesophageal carcinoma (ESCA) and head and neck
squamous cell carcinoma (HNSC) tissue (l) and tumour tissue (m). p = p-value of
Spearman correlation coefficient. Shown is mean +/- SD (e,i,j). Two-sided
Šídák’s test (e,i). Exact p-values are indicated.
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Extended Data Fig. 2 | NSUN3 regulates mitochondrial activity. a. Western
blot for NSUN3, MT-CO1, and MT-CO2 in SCC25 cells infected with control
(Ctr) and NSUN3 shRNAs (#1, #2). HSP90: loading control. b. Quantification
of NSUN3 protein levels in mitochondria isolated from the indicated
subpopulations (n = 4 flow sorts). c. Illustration of the TCA cycle and its
intermediate metabolites. d. Relative RNA levels of NSUN3 in the indicated cell
lines expressing wild-type (WT) or methylation-deficient mutated (MUT)
NSUN3 proteins (n = 3 RT–qPCRs). e. Fluorescence staining of GFP and
MitoTracker Deep Red in VDH15 cells infected with WT or MUT NSUN3.
Representative immunofluorescence from 30 stained cells. f. Sequence of

NSUN3 constructs showing the substitution of cysteine (NSUN3WT) with alanine
(NSUN3MUT). g-i. Representative images showing media colour of the indicated
cells infected with Ctr or NSUN3 shRNAs after 48 h in culture. j-n. Oxygen
consumption rate (OCR) (j,k) and extracellular acidification rate (ECAR) (l-n) in
the indicated cell lines infected with Ctr or NSUN3 shRNAs (sh#1, sh#2). (j: n = 5;
k: shCtr n = 4, sh#1 n = 5, sh#2 n = 6; l: shCtr n = 5, sh#1 n = 7; m: shCtr n = 5, sh#1
n = 6; n: shCtr n = 4, sh#1 n = 5 injections). o. ECAR in VDH15 cells infected with
empty vector (ctr_ev), NSUN3WT or NSUN3MUT constructs (Ctr_ev, NSUN3WT: n = 4
injections; NSUN3MUT: n = 6 injections). Shown is mean +/- SD (b,d,j-o).
Two-sided Tukey’s test (b) or Šídák’s test (d). Exact p-values are indicated.

Extended Data Fig. 3 | See next page for caption.
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Extended Data Fig. 3 | NSUN3 regulates mitochondrial function and shape.
a. Percentage of live or dead cells using Annexin V and Propidium iodide (PI)
staining of indicated cell lines infected with Control (Ctr) or NSUN3 shRNAs
(sh#1, sh#2) or NSUN3 overexpression constructs containing wild-type (WT)
or mutated (MUT) NSUN3, or the empty vector as a control (Ctr_ev) (n = 3
infections). b. Quantification of the mitochondrial DNA copy number in shCtr
or NSUN3-depleted (sh#1, sh#2) FaDu cells (n = 3 infections). c. MitoSOX flow
cytometry to quantify cellular ROS production in the indicated cells (n = 3
infections). d. Quantification of average mitochondrial length in VDH15 cells
infected with NSUN3WT or NSUN3MUT constructs (NSUN3WT n = 18; NSUN3MUT:
n = 14 cells). e. Fluorescent staining for overexpressed NSUN3 (GFP) and

Phalloidin in VDH15 cells infected with NSUN3WT or NSUN3MUT constructs.
Representative immunofluorescence out of 30 stained cells. f-h. Electron
microscopy of FaDu cells infected with control (shCtr) or NSUN3 shRNAs (sh#1).
Higher magnifications of mitochondria are shown in (h). Representative
images from 10 cells per condition from 2 independent experiments.
(i-k) Quantification of cristae per mitochondria (i,j) and circularity ratio (k) in
the indicated cells (i: Ctr n = 118, sh#1 n = 116, sh#2: n = 117; j: Ctr n = 125, sh#1
n = 124, sh#2: n = 112; k: Ctr n = 103, sh#1 n = 131, sh#2: n = 115 mitochondria in 10
different cells from 2 independent experiments). Shown is mean +/- SD (a-d, i-k).
Two-sided Šídák’s test (c,i-k). Two-tailed unpaired t-test (d). Exact p-values are
indicated.

Extended Data Fig. 4 | NSUN3-deficient tumours switch to glycolysis and
fail to metastasize. a, b. Bioluminescence imaging (a) and tumour occurrence
(b) of primary tumours (PT), lymph node (LN) or lung metastases (Met), 21 days
after orthotopic transplantations. Tumours derived from SCC25 or VDH15
cells infected with control (shCtr) or two different NSUN3 shRNAs (#1, #2).
c-f. Dimension of the metastasis relative to its matching primary tumour (c)
quantified by measuring the relative luminescence signal shown in (a), and
tumour growth (d-f) of tumours derived from SCC25 (c,d; upper panels; n = 10
mice per condition), VDH15 (c,d; lower panels; n = 10 mice per condition) and
VDH01 (e,f) cells infected with shCtr or shRNAs #1 or #2) (c,d,e), or with an
empty vector control (Ctr_ev), a wildtype (WT), or mutant (MUT) NSUN3
overexpression construct (f; shCTR: n = 7 mice; sh#1, sh#2: n = 6 mice; Ctr_ev:
n = 9 mice; WT, MUT: n = 10 mice). g. Immunostaining for GLUT1 in shCtr or

shNSUN3 (sh#1, sh#2) infected SCC25 PTs. h-t. Hematoxylin and eosin (h,l,p),
immunofluorescence (i-k; m-o; q-s) and quantification (t) of SCC25- and
VDH15-derived primary tumours (day 21) infected with shCtr (upper panels),
shNSUN3#1 (middle panels) or shNSUN3#2 (lower panels) stained for keratin 10
(K10), CD44, filaggrin (FLG) and DAPI as a nuclear counterstain (SCC25 CD44
and K10 staining: shCTR: n = 33, sh#1 n = 26, sh#2 n = 25 tumours areas from 3
mice; SCC25 FLG staining: shCTR: n = 46, sh#1 n = 35, sh#2 n = 33 tumour areas
from 3 mice; VDH15: shCTR: n = 6, sh#1 n = 5, sh#2 n = 11 tumour areas from 3
mice). Representative images from 3 mice per condition (g,h-s). Scale bar:
100 μm. Box plot shows minimum, first quartile, median, third quartile, and
maximum (c). Shown is mean +/- SEM (d-f) or SD (t). Chi-squared test (b).
Two-tailed Mann Whitney test (c), or two-sided Dunnett’s test (d) and Šídák’s
test (t). Exact p-values are indicated.
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Extended Data Fig. 5 | Mitochondria-driven gene signatures in primary
tumours. a, b. Illustration (a) of GFP-positive primary tumours in mouse
tongues (b). c. RNA read counts for NSUN3 in control (shCtr) or NSUN3 shRNAs
(sh#1 plus sh#2) primary tumours (shCtr n = 4 mice/tumours; shNSUN3: n = 7
mice/tumours). d. Correlation heat map of VDH15 primary tumour samples
subjected to RNA-seq. e-f. Volcano plots of differentially expressed genes in
VDH15 primary tumours infected with shCtr or the NSUN3 shRNAs sh#1 (e) or
sh#2 (f). g. Overlap of differentially expressed genes in tumours infected with
shNSUN3#1 or #2. h. GO analysis (GOrilla) for commonly differentially

expressed genes shown in (g) (n = 1708). P value: Exact p-value for the observed
enrichment. i. Heat map showing differentially expressed (p ≤ 0.05) transcripts
from GO:0003735 in control (Ctr) or shNSUN3#1/#2 (NSUN3) primary
tumours. j. Principal component (PC) analysis using expression values of
mitochondrial regulators (MitoCarta2.0) in shCtr or shNSUN3 (sh#1, sh#2)
tumour cells. k. Correlation of mitochondrial regulators expression in
shNSUN3#1 and shNSUN3#2 tumour cells (r2= coefficient of determination).
Shown is mean +/- SD (c). Two-tailed unpaired t-test (c). Wald test (e-g). Pearson
r (k). Exact p-values are indicated.

Extended Data Fig. 6 | NSUN3 is dispensable for tumoroid growth.
a-d. Immunostaining (a,c) and fluorescence intensity (b,d) of MT-CO2 or
MT-CO1 and CD44 in the outlined area (dotted square) in SCC25 primary
tumours at day 21. Shown are representative stainings from 4 mice. e-l. Bright
field images (e-k) and illustration of 3D cultures (l) of tumoroids derived from
the indicated tumour cells infected with shRNA control vector (shCtr), shRNA
targeting NSUN3 (shNSUN3), control empty vector (Ctr_ev), NSUN3 wild-type
(WT) or NSUN3 mutated overexpression construct (MUT) after 7 days. Shown

are representative images from 3 independent experiments. m-p. Representative
stainings (m-o) and quantification (p) of glucose uptake using 2DG-IR in control
(shCtr) or NSUN3 shRNAs (sh#1, #2) FaDu-derived tumoroids (shCTR, sh#1:
n = 8; sh#2 n = 6 tumoroids). DAPI: nuclear counterstain (a,c). Scale bar: 50 μm
(a,c,e,f,I,j); 30 μm (g,h,k); 100 μm (m-o). Box plot shows minimum, first
quartile, median, third quartile, and maximum (p). Two-sided Dunnett’s test
(p). Exact p-values are indicated.
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Extended Data Fig. 7 | Spatial mitochondrial activity in tumoroids.
a-d. Immunofluoresence (a,c) and quantification (b,d) of MitoTracker
(CMXROS) and Phalloidin (Phall) in 7 days cultured Fadu (a,b) or VDH01
(c,d)-derived tumoroids. e. Schematic representation of 3D culture assays and
subsequent sectioning. Hematoxylin & Eosin staining of sectioned tumoroids
(lower left) and invading tumoroids (lower right). f-k. Immunofluorescence
(f,g,i,j,k) and quantification (h) of MT-CO1 and Phalloidin (Phall) in sectioned

7 days cultured FaDu-derived tumoroids. Shown are representative images
from at least 3 independent experiments (a,c,f,g,i-k). l-n. Representative
images (l,m) and quantification (n) of invading leader cells per tumoroid in
shCtr and shNSUN3 infected VDH15 tumoroids. (shCTR n = 23; sh#1 n = 13
tumoroids). Scale bars: 30 μm (a); 40 μm (f,l,m); 50 μm (c). Box plot shows
minimum, first quartile, median, third quartile, and maximum (n). Two-tailed
unpaired t-test (n). Exact p-values are indicated.

Extended Data Fig. 8 | Metastasis-initiating cells require NSUN3. a-c. Flow
cytometry of VDH15 (a), SCC25 (b) and VDH01 (c) cells for CD36 and CD44 (left
panels) and quantification of the MMP (right panels; n = 3 flow sorts) in the
indicated subpopulations. d, e. Fold change (FC) of mRNA levels of CD36,
CD44, KRT10 (d) and MT-CO1, TFAM, SLUG, ITGA6 and KRT8 (e) in FaDu
subpopulations (n = 9: 3 RT–qPCRs from 3 infections). f. Log 2 FC in RNA levels of
NSUN3, CD44 and CD36 in FaDu cells infected with a control shRNA (shCtr) or
shRNAs for NSUN3 (shNSUN3#1/#2) (n = 6: 2 RT–qPCRs from 2 infections).
g. Log 2 FC of NSUN3, CD36 and CD44 RNA levels in FaDu subpopulations
infected with sh#2 relative to shCtr (n = 6 or 4 RT–qPCRs from two flow sorts).
h-i. Representative flow cytometry plots for CD36 and CD44 from tumour cells
expressing (shCtr) (h) or lacking (shNSUN3#1) NSUN3 (i). j. Percentage of cells

in the indicated sorted populations in from VDH15, SCC25 and FaDu tumoroids
infected with shCtr or sh#1 (shCtr VDH15, shCtr FaDu, sh#1 SCC25, sh#1 FaDu:
n = 3 flow sorts; shCtr SCC25, sh#1 VDH15 n = 4 flow sorts). k-l. Log 2 FC of
NSUN3, CD44 and CD36 RNA levels in FaDu (k) or VDH15 (l) cells infected with
an empty vector control (Ctr_ev), NSUN3 wild-type (WT) or NSUN3 mutated
(MUT) overexpressing construct (n = 3 RT–qPCRs). m. Percentage of cells in the
indicated sorted populations from VDH15 tumoroids infected with Ctr_ev,
NSUN3WT or NSUN3MUT constructs (n = 3 infections). Shown is mean +/- SD
(a-c,f,k-m). Box plot shows minimum, first quartile, median, third quartile, and
maximum (d,e,g). Two-sided Tukey’s test (a-f), or Šídák’s test (j). Two-tailed
Unpaired t-test (k-m). Exact p-values are indicated.
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Extended Data Fig. 9 | A mitochondria-driven proteome defines
metastasis-initiating cells. a. Heat map of differentially translated mRNAs
(p < 0.05) encoding proteins of the mitochondrial inner membrane, the
oxidative phosphorylation pathway or cell adhesion molecules in the indicated
CD44/CD36 subpopulation. H: high; L: low. b. GSEA on CD44HCD36L versus
CD44HCD36H newly synthesized proteins showing normalized enrichment
scores (NES) and adjusted p-values. c-e. Translation level of the differentiation
marker sciellin (SCEL) (c), the proliferation marker cell division cycle associated
8 (CDCA8) (d), and CD44 (e) in the indicated cell populations.
f-h. Representative flow cytometry plot for CD36 and CD44 (f, g) and
quantification of CD36 protein levels (h) in tumour cells expressing control
empty vector (Ctr_ev) or CD36 overexpression constructs (CD36 OEX).
i-j. Relative log 2 fold change (FC) of CD36 (i) and NSUN3 (j) RNA in VDH01 cells

infected with a control shRNA (shCtr), two different shRNAs for NSUN3
(shNSUN3#1/#2), or the Ctr_ev and CD36OEX constructs. (n = 3 infections).
k. Representative bright field images of VDH01 spheres infected with shCtr or
shNSUN3#1 or #2), Ctr_ev, or CD36 OEX constructs (n = 3 infections).
l-m. Quantification of maximal oxygen consumption rate (OCR) in VDH15 cells
infected shCtr, shNSUN3#1 or #2, Ctr_ev, or CD36 OEX constructs (n = 7
injections). n. Treatment and time line for invasion assays. o. Quantification
of the GFP signal in cells over time after infection with shCTR or shRNA
targeting NSUN3 (n = 3 infections). Shown is mean +/- SD (c-e, h-j,l-o). Random
permutations (b). Unpaired, two-sided Student’s t-test in which P values were
adjusted by Benjamini-Hochberg FDR correction (c-e). Unpaired two-tailed
t-test (h) or two-sided Šídák’s test (i,j,m). Exact p-values are indicated
c-e,h-j,l,m).

Extended Data Fig. 10 | NSUN3-driven gene signatures in patients with
HNSCC. a, b. Representative immunohistochemistry for NSUN3 in primary oral
(OSCC) or laryngeal (LaSCC) squamous carcinomas from 28 patients classified
by pathological N stage with no (N0), 19 patients with one (N1: 19) or 32 patients
with multiple (N2-3) metastases (a) or in the indicated pathological
stages (I–II: n = 25 patients, III–IVa-b: n = 52) (b). Scale bar: 100 μm.
c, d. Immunohistochemistry (c) and quantification (d) of NSUN3 protein levels
in primary tumours (PTU; n = 17) and matching lymph node metastases

(LN; n = 22) at the time of diagnosis. Dotted line: matching LN metastases.
e. Flowchart to identify 4 clusters (C1-C4) of HNSCC patients (TCGA) based on
NSUN3-driven gene signatures. f. Normalized enrichment scores (NES) and
adjusted p-values (random permutations) for the indicated differentially
expressed gene sets. g. Heat map showing 4 clusters (C1-C4) for unsupervised
hierarchical clustering based on transcript levels of top 50 genes (gene set
NSUN3High) and bottom 50 genes (gene set NSUN3Low). NSUN3 expression in
each tumour is represented as low (blue), middle (green), and high (red).
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Extended Data Fig. 11 | See next page for caption.

Extended Data Fig. 11 | Pharmacological inhibition of mitochondrial
translation mimics loss of mitochondrial m5C and f5C. a. Schematic
overview of inhibition of mitochondrial translation by selected antibiotics.
b. Molecular structure of the indicated antibiotics. c. Flow cytometry plots for
MPP (MitoTracker DR) and OP-puro incorporation in FaDu cells exposed to the
indicated antibiotics or vehicle control (CTR) for 48 h. d. Oxygen consumption
rate (OCR; upper panels) and extracellular acidification rate (ECAR; lower
panels) in CTR or antibiotics-treated cells (CTR: n = 11, CAP: n = 8, TIG: n = 5,
DOX: n = 8, LIN: n = 6, AMOX: n = 8, AMP: n = 6 independent injections).
e, f. Collagen-invading VDH01-derived tumoroids treated with tigecycline

(TIG) or vehicle control (CTR) for 48 h (e) and quantification of leader cells (f)
(CTR: n = 20, TIG: n = 23 tumoroids). g, h. Immunolabelling (g) and
quantification (h) of glucose uptake through 2DG-IR in CTR- or TIG-treated
tumoroids for 48 h (CTR: n = 6, TIG: n = 5 tumoroids). i-m. CD36 protein
expression (i) and quantification of the indicated CD36/CD44 cell populations
(j-l) in flow-sorted SCC25-derived tumoroids (m) (n = 3 drug treatments).
Shown is mean +/- SD (d, i-l). Box plot shows minimum, first quartile, median,
third quartile, and maximum (f,h). Two-tailed unpaired t-test (f,h) or two-sided
Šídák’s test (j-l). Exact p-values are indicated.
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Extended Data Fig. 12 | Cell survival and tumour growth are unaffected by
inhibition of mitochondrial translation. a, b. Representative flow cytometry
plots (a) and percentages (b) of live or dead cells after Annexin V and PI staining
of indicated cell lines treated for 48 h with indicated antibiotics (n = 3 drug
treatments) c. Tumour size quantified by measuring the relative photon flux of

the luminescence signal at the indicated time points in SCC25- (left panel) or
VDH01 (right panel)-derived tumours (SCC25 CTR: n = 8 mice, AMOX: n = 9
mice, DOX: n = 8 mice, DOX: n = 9 mice; VDH01 CTR, TIG, DOX: n = 8 mice,
AMOX: n = 9 mice). Shown is mean +/- SD (b,c).

